• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经动脉化疗栓塞治疗肝细胞癌中炎症指标的预后意义:系统评价和荟萃分析。

Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis.

机构信息

Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People's Republic of China.

State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang province, People's Republic of China.

出版信息

PLoS One. 2020 Mar 26;15(3):e0230879. doi: 10.1371/journal.pone.0230879. eCollection 2020.

DOI:10.1371/journal.pone.0230879
PMID:32214401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7098645/
Abstract

OBJECTIVES

To investigate the association between inflammatory indices and clinical outcomes of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) by performing meta-analysis.

METHODS

A systematic literature search for relevant studies published up to August 2019 was performed by using PubMed, Web of Science, EMBASE, China National Knowledge Internet (CNKI) and Wanfang databases. Pooled hazard ratios (HR) or odds ratio (OR) and 95% confidence intervals (95% CI) were calculated.

RESULTS

A total of 5280 patients from 22 studies were finally enrolled in the meta-analysis. The results demonstrated that elevated preoperative NLR, PLR, and CRP was associated with poor OS in HCC patients treated by TACE (HR = 1.81, P<0.00001; HR = 1.56, P = 0.007; HR = 1.45, P<0.00001, respectively). In addition, high NLR was significantly correlated with the presence of tumor vascular invasion (OR = 1.49, P = 0.002). Elevated PLR tended to be correlated with higher incidence of tumor size>3 cm (OR = 2.42, P = 0.005).

CONCLUSIONS

Elevated preoperative NLR, PLR, and CRP are associated with poor prognosis in HCC patients treated with TACE. These inflammatory indices may be convenient, accessible, affordable and dependable biomarkers with prognostic potential for HCC patients treated by TACE.

摘要

目的

通过荟萃分析研究炎症指标与接受经动脉化疗栓塞(TACE)治疗的肝细胞癌(HCC)患者临床结局之间的相关性。

方法

系统检索 PubMed、Web of Science、EMBASE、中国知网(CNKI)和万方数据库截至 2019 年 8 月发表的相关研究。计算汇总风险比(HR)或比值比(OR)及其 95%置信区间(95%CI)。

结果

共纳入 22 项研究的 5280 例患者,Meta 分析结果显示,术前 NLR、PLR 和 CRP 升高与 TACE 治疗的 HCC 患者 OS 不良相关(HR=1.81,P<0.00001;HR=1.56,P=0.007;HR=1.45,P<0.00001)。此外,高 NLR 与肿瘤血管侵犯显著相关(OR=1.49,P=0.002)。PLR 升高与肿瘤直径>3cm 的发生率升高有关(OR=2.42,P=0.005)。

结论

术前 NLR、PLR 和 CRP 升高与接受 TACE 治疗的 HCC 患者预后不良相关。这些炎症指标可能是预测 TACE 治疗 HCC 患者预后的简便、易得、经济且可靠的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/3dba772ad165/pone.0230879.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/e2be0ea9c938/pone.0230879.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/2f197f90f67c/pone.0230879.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/f835288ff6fc/pone.0230879.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/3dba772ad165/pone.0230879.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/e2be0ea9c938/pone.0230879.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/2f197f90f67c/pone.0230879.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/f835288ff6fc/pone.0230879.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27fe/7098645/3dba772ad165/pone.0230879.g004.jpg

相似文献

1
Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis.经动脉化疗栓塞治疗肝细胞癌中炎症指标的预后意义:系统评价和荟萃分析。
PLoS One. 2020 Mar 26;15(3):e0230879. doi: 10.1371/journal.pone.0230879. eCollection 2020.
2
Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.经动脉化疗栓塞术与肝切除术治疗肝细胞癌的比较:一项荟萃分析。
Drug Des Devel Ther. 2015 Aug 10;9:4431-40. doi: 10.2147/DDDT.S86629. eCollection 2015.
3
Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.单纯肝切除术与联合术前及术后经动脉化疗栓塞术治疗肝细胞癌:一项系统评价和荟萃分析。
Oncotarget. 2015 Nov 3;6(34):36838-59. doi: 10.18632/oncotarget.5426.
4
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为经动脉化疗栓塞术后复发性肝细胞癌生存和转移的预测指标
PLoS One. 2015 Mar 5;10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.
5
Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis.中性粒细胞与淋巴细胞比值对肝细胞癌的预后意义:一项荟萃分析。
BMC Cancer. 2014 Feb 21;14:117. doi: 10.1186/1471-2407-14-117.
6
Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.炎症评分可预测接受经动脉化疗栓塞术和重组人5型腺病毒H101治疗的肝细胞癌患者的生存情况。
PLoS One. 2017 Mar 29;12(3):e0174769. doi: 10.1371/journal.pone.0174769. eCollection 2017.
7
Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为不同治疗方式下肝细胞癌患者预后预测指标的Meta分析与系统评价
Cell Physiol Biochem. 2017;44(3):967-981. doi: 10.1159/000485396. Epub 2017 Nov 27.
8
Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis.术后辅助性经动脉化疗栓塞术对所有合并微血管侵犯的肝细胞癌患者均有益吗:一项荟萃分析
Scand J Gastroenterol. 2019 May;54(5):528-537. doi: 10.1080/00365521.2019.1610794. Epub 2019 May 12.
9
Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.血浆微小RNA-122作为肝细胞癌患者经动脉化疗栓塞术后治疗反应的预测标志物。
J Gastroenterol Hepatol. 2017 Jan;32(1):199-207. doi: 10.1111/jgh.13448.
10
Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.肿瘤大小影响伴有微血管侵犯的肝细胞癌患者辅助经动脉化疗栓塞的疗效。
Oncologist. 2019 Apr;24(4):513-520. doi: 10.1634/theoncologist.2018-0305. Epub 2018 Dec 14.

引用本文的文献

1
A preoperative inflammatory score-based nomogram predicts overall survival after curative hepatectomy for hepatocellular carcinoma.基于术前炎症评分的列线图可预测肝细胞癌根治性肝切除术后的总生存期。
Discov Oncol. 2025 Aug 31;16(1):1659. doi: 10.1007/s12672-025-03406-1.
2
Which is the best TACE agent for patients with different NLR hepatocellular carcinomas? A systematic review and network meta-analysis.对于不同中性粒细胞与淋巴细胞比值(NLR)的肝细胞癌患者,哪种经动脉化疗栓塞(TACE)药物最佳?一项系统评价和网状Meta分析。
Heliyon. 2024 May 4;10(9):e30759. doi: 10.1016/j.heliyon.2024.e30759. eCollection 2024 May 15.
3
A Multicenter International Retrospective Investigation Assessing the Prognostic Role of Inflammation-Based Scores (Neutrophil-to-Lymphocyte, Lymphocyte-to-Monocyte, and Platelet-to-Lymphocyte Ratios) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Undergoing Chemoembolizations of the Liver.

本文引用的文献

1
C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.C 反应蛋白是肝移植后肝细胞癌复发的独立预测因子。
PLoS One. 2019 May 29;14(5):e0216677. doi: 10.1371/journal.pone.0216677. eCollection 2019.
2
Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.一种包含中性粒细胞与淋巴细胞比值的新列线图的开发,用于预测接受经动脉化疗栓塞的肝细胞癌患者的生存情况。
Cancers (Basel). 2019 Apr 10;11(4):509. doi: 10.3390/cancers11040509.
3
The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy.
一项多中心国际回顾性调查,评估基于炎症的评分(中性粒细胞与淋巴细胞比值、淋巴细胞与单核细胞比值以及血小板与淋巴细胞比值)在接受肝动脉化疗栓塞术的中期肝细胞癌(HCC)患者中的预后作用。
Cancers (Basel). 2024 Apr 23;16(9):1618. doi: 10.3390/cancers16091618.
4
Immune Effects of Intra-Arterial Liver-Directed Therapies.经动脉肝脏靶向治疗的免疫效应。
J Vasc Interv Radiol. 2024 Feb;35(2):178-184. doi: 10.1016/j.jvir.2023.10.019.
5
Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.预测接受经动脉化疗栓塞术的不可切除肝细胞癌患者预后的列线图的开发与验证
Clin Med Insights Oncol. 2023 Jun 22;17:11795549231178178. doi: 10.1177/11795549231178178. eCollection 2023.
6
Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology.中性粒细胞与淋巴细胞比值(NLR)、淋巴细胞与单核细胞比值(LMR)、血小板与淋巴细胞比值(PLR)及淋巴细胞与C反应蛋白比值(LCR)在接受肝脏化疗栓塞术(TACE)的肝细胞癌(HCC)患者中的预后作用:连接肿瘤微环境、生物标志物与介入放射学的未探索领域
Cancers (Basel). 2022 Dec 30;15(1):257. doi: 10.3390/cancers15010257.
7
Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers.炎症指标作为老年肝细胞癌患者生存的预后因素:一项对斯洛伐克八个中心的病例对照研究。
J Clin Med. 2022 Jul 19;11(14):4183. doi: 10.3390/jcm11144183.
8
Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations.肝细胞癌的局部和区域治疗及未来联合治疗
Cancers (Basel). 2022 May 17;14(10):2469. doi: 10.3390/cancers14102469.
9
Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.肝细胞癌的局部区域治疗:疗效和未来前景。
World J Gastroenterol. 2021 Nov 21;27(43):7462-7479. doi: 10.3748/wjg.v27.i43.7462.
10
Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort.炎症评分:北美队列中接受经动脉化疗栓塞的肝癌患者的比较与效用
J Hepatocell Carcinoma. 2021 Dec 1;8:1513-1524. doi: 10.2147/JHC.S335183. eCollection 2021.
中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值联合应用于接受经动脉化疗栓塞治疗的肝细胞癌患者的预后及预测价值。
Cancer Manag Res. 2019 Feb 12;11:1391-1400. doi: 10.2147/CMAR.S190545. eCollection 2019.
4
Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma.经动脉化疗栓塞术对部分晚期肝细胞癌患者的良好生存预后相关
J Cancer. 2019 Jan 1;10(3):665-671. doi: 10.7150/jca.28528. eCollection 2019.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
Prognostic Role of Platelet-to-Lymphocyte Ratio in Hepatocellular Carcinoma with Different BCLC Stages: A Systematic Review and Meta-Analysis.血小板与淋巴细胞比值在不同BCLC分期肝细胞癌中的预后作用:一项系统评价和Meta分析
Gastroenterol Res Pract. 2018 Aug 8;2018:5670949. doi: 10.1155/2018/5670949. eCollection 2018.
7
The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis.术前中性粒细胞与淋巴细胞比值对接受肝切除术的肝细胞癌患者的预后意义:系统评价和荟萃分析。
Int J Surg. 2018 Jul;55:73-80. doi: 10.1016/j.ijsu.2018.05.022. Epub 2018 May 19.
8
Mesenchymal stromal cell therapy for liver diseases.间质基质细胞治疗肝脏疾病。
J Hepatol. 2018 Jun;68(6):1272-1285. doi: 10.1016/j.jhep.2018.01.030. Epub 2018 Feb 7.
9
Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization.中性粒细胞与淋巴细胞比值及天冬氨酸与丙氨酸转氨酶比值可预测经动脉栓塞术后肝细胞癌的预后。
Medicine (Baltimore). 2017 Nov;96(45):e8512. doi: 10.1097/MD.0000000000008512.
10
Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.炎症标志物作为接受经动脉化疗栓塞的肝细胞癌患者生存的预后因素
Gastroenterol Res Pract. 2017;2017:4164130. doi: 10.1155/2017/4164130. Epub 2017 Aug 15.